

Beata Sieklucka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1621537/publications.pdf>

Version: 2024-02-01

26
papers

229
citations

1040056

9
h-index

996975

15
g-index

28
all docs

28
docs citations

28
times ranked

344
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatty Acid-Binding Protein 7 (FABP-7), Glutamic Acid and Neurofilament Light Chain (NFL) as Potential Markers of Neurodegenerative Disorders in Psoriatic Patientsâ€”A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2430.	2.4	5
2	Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 535-548.	5.2	18
3	Vitamin K and D Supplementation and Bone Health in Chronic Kidney Diseaseâ€”Apart or Together?. <i>Nutrients</i> , 2021, 13, 809.	4.1	15
4	MO564CHRONIC EXPOSURE TO INDOXYL SULFATE CHANGES BONE PROPERTIES AND EXPRESSION OF SIRT2, SIRT3, AND SIRT7 GENES*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
5	Paracrine Kynurenic Pathway Activation in the Bone of Young Uremic Rats Can Antagonize Anabolic Effects of PTH on Bone Turnover and Strength through the Disruption of PTH-Dependent Molecular Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6563.	4.1	3
6	MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3203.	3.7	9
7	Preclinical Toxicity and Safety of MM-129â€”First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer. <i>Pharmaceutics</i> , 2021, 13, 1222.	4.5	6
8	Serum PTH, PTH1R/ATF4 pathway, and the sRANKL/OPG system in bone as a new link between bone growth, cross-sectional geometry, and strength in young rats with experimental chronic kidney disease. <i>Cytokine</i> , 2021, 148, 155685.	3.2	2
9	P0871THE IMPACT OF ENDOGENOUS PTH/PTH1R/ATF4 AXIS ON TRABECULAR AND CORTICAL BONE REMODELING AND BONE GROWTH OF YOUNG RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASES. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
10	Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5979.	4.1	6
11	The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 1697-1711.	5.2	4
12	Astrogliosis in an Experimental Model of Hypovitaminosis B12: A Cellular Basis of Neurological Disorders due to Cobalamin Deficiency. <i>Cells</i> , 2020, 9, 2261.	4.1	7
13	P0870THE ACTIVATION OF KYNURENIC SYSTEM IN BONE TISSUE AS A NEW REGULATOR OF OSTEOBLASTOGENESIS IN RATS WITH EXPERIMENTAL CHRONIC KIDNEY DISEASE DURING LP533401 THERAPY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
14	P0874THE IMPACT OF CHRONIC EXPOSURE TO INDOXYL SULFATE ON BONE TURNOVER MARKERS, PTH, VITAMIN D3, AND BIOMECHANICAL AND DENSITOMETRIC PROPERTIES OF BONES IN RAT MODEL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
15	INTRACELLULAR MECHANISMS OF TUMOR CELL IMMUNORESISTANCE. <i>Acta Biochimica Polonica</i> , 2020, 67, 143-148.	0.5	2
16	Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 165528.	3.8	4
17	FP443THE INFLUENCE OF TRYPTOPHAN HYDROXYLASE INHIBITOR LP533401 ON KYNURENINE CONCENTRATION IN BONE TISSUE IN THE EXPERIMENTAL MODEL OF CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
18	RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia. <i>Cytokine</i> , 2018, 106, 19-28.	3.2	12

#	ARTICLE	IF	CITATIONS
19	LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys. <i>Bone</i> , 2018, 113, 124-136.	2.9	10
20	Does the OPG/RANKL system contribute to the bone-vascular axis in chronic kidney disease? A systematic review. <i>Advances in Medical Sciences</i> , 2017, 62, 52-64.	2.1	16
21	The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease. <i>Bone</i> , 2017, 105, 1-10.	2.9	23
22	Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease. <i>Frontiers in Physiology</i> , 2017, 8, 836.	2.8	34
23	A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease. <i>PeerJ</i> , 2017, 5, e3199.	2.0	7
24	The Biomechanical Testing for the Assessment of Bone Quality in an Experimental Model of Chronic Kidney Disease. <i>Nephron</i> , 2016, 132, 51-58.	1.8	22
25	The Association between Elevated Levels of Peripheral Serotonin and Its Metabolite "5-Hydroxyindoleacetic Acid and Bone Strength and Metabolism in Growing Rats with Mild Experimental Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0163526.	2.5	23
26	A view at monoclonal antibodies in therapy of osteoporosis. <i>Polish Annals of Medicine</i> , 2015, 22, 149-154.	0.3	1